-

BurgerFi International, Inc. (BFI) Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against BurgerFi International, Inc. f/k/a Opes Acquisition Corp.

SAN DIEGO--(BUSINESS WIRE)--The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired BurgerFi International, Inc. (NASDAQ: BFI) common stock between December 17, 2020 and November 15, 2022, for violations of the Securities Exchange Act of 1934. Following the business combination between Opes Acquisition Corp. and Legacy BurgerFi International, the Company, with its subsidiaries, has owned and franchised fast-casual and premium-casual dining restaurants.

What Now: Similarly situated shareholders may be eligible to participate in the class action against BurgerFi. Shareholders who want to act as lead plaintiff for the class must file their papers by June 5, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

What is this Case About: BurgerFi International, Inc. (BFI) Misled Investors Regarding its Business Prospects

According to the complaint, the Company announced it had completed a business combination between Opes Acquisition Corp. and Legacy BurgerFi on December 17, 2020. On November 4, 2021, the Company completed its acquisition of Anthony's Coal Fired Pizza & Wings and touted the acquisition as "a significant step forward in BurgerFi's ongoing growth strategy and transition into a premium multibrand platform."

During the class period, defendants failed to disclose that the Company had overstated the effectiveness of its acquisition and growth strategies and had misrepresented to investors the purported benefits of Anthony’s Acquisition and its post-business combination business and financial prospects.

On August 11, 2022, BurgerFi issued a press release announcing the Company's second quarter 2022 results, reporting it had missed consensus estimated by $2.28 million. The Company also disclosed that “[n]et loss in the second quarter was $60.4 million compared to a net income of $9.0 million in the year-ago quarter[,]” which “[wa]s primarily the result of goodwill impairment charges of $55.2 million in relation to BurgerFi and Anthony’s coupled with higher depreciation, amortization of intangibles, share-based compensation, interest expense resulting from the acquisition-related debt.” On this news, BurgerFi's stock price fell $.10 per share, or 3.03%, to close at $3.20 per share on August 11, 2022.

Then, on November 16, 2022, BurgerFi announced its third quarter 2022 results, missing consensus estimates by $0.84 million, explaining that “[f]or the BurgerFi brand, same-store sales decreased 11% and 6% in corporate-owned and franchised locations, respectively.” On this news, BurgerFi's stock price fell $0.24 per share, or over 10%, to close at $2.03 per share on November 16, 2022.

Contact us to learn more:
Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against BurgerFi International, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:BFI

Release Summary
BurgerFi International, Inc. (BFI) Misled Investors Regarding its Business Prospects
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Regencell Bioscience Holdings Limited Class Action Reminder - Robbins LLP Encourages RGC Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

POET Technologies Inc. Class Action Reminder - Robbins LLP Encourages POET Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POET Technologies Inc. (NASDAQ: POET) securities between April 1, 2026 and 8:57 A.M. ET on April 27, 2026. POET Technologies describes itself as a "design and development company offering photonic integrated packaging solutions based on the POET Optical Interposer™, a novel platform that allows the seamless integration of electronic and photoni...

Immutep Limited Class Action Reminder - Robbins LLP Encourages IMMP Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug CandidateOn May 5, 2026, a class action was filed on behalf of all investors who purchased or otherwise acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related i...
Back to Newsroom